well.. think of it this way.. this way, they won't have to worry about financing if interim is a success.. just sell on market up to 30m w/o having to have secondary offering. neutral news imo.
i can see your numbers playing out.... im dumbfounded as to why WS don't see this.
I hope we repeat the phase II and that EORTC data for control happens in our trials.
Since data is not yet mature, i can see your 11 vs 19, and where final would be 12 vs 21.
eagerly waiting for the results.
im still here. ... im kinda surprised we are up today lol when dow is down over 300! we are up 2 pennies.
waiting for interim result.. 2 more months.
only 8? either it will be mid double digits or low 3s, pending interim of course.
after that it's a waiting game until mid 2015. then u will see taking off to double digits before the results.
well now that you mention it.. it does sound a bit negative.
I will try from here to only post AWESOME and GOOD stuff.
CEO said this is a registrational trial which means if successful, it will lead to NDA. Agreed.
thanks again for the DD. For some reasons, small samples always tend to lead to higher OS.. selection bias perhaps. 9 month vs 14 should lead to approval. This will probably take 2 years to recruit and another year to see the data. Long away, yet exciting nevertheless.
Lets croxx our fingers for the interim in the meantime.. I hope we see some PR saying the 235 event has occurred.
Although it was small sample, TH-302 worked great for NSCLC. If our phase II can repeat it, we will be in great shape, better than the Tarceva you just reminded us of. Thanks.
Man the waiting is killing me lol. enjoy football in the meantime. GO USA!
Its free money to our company if it succeeds and he is mad i found the info????
Who is the the true short?
That failed trial 7 years ago, if you exclude those that were diabetic, it woulda probably made it.
Yea yea, that drug has been bounced around, but hey, it costs us ZERO dollar and we get to keep 50 percent of the profits if it gets approved... that sounds better than the Merck DEAL if you ask me, percentage wise.
But then again, you don't like GLUFOSFAMIDE.
I'll take anything that can make me free $$$$$$$$$$$$$$$. FREEEEE!
Just incase you can't read the whol thing Beachbum...
A key finding of the prior phase III study was the shortened survival associated with glufosfamide treatment of insulin-taking patients (43 of 303 test subjects).
Yea, your failed trial 7 years ago helped to start this new trial that has a great chance imo.
but then again, you are short, so you don't give a chit if glufosfamide succeeds and Threshold make $$$$$$ right?
Who's the real short?
I.D.I.O.T if i ever saw one.
IM sure you know more than Eleison Pharma and the experts oncologist advisors.
Sell and short away. I think there is a chance this can be money maker for THLD as well as TH302.
Glufosfamide is an analog of a widely used chemotherapeutic agent (ifosfamide), but with greater specificity and a better safety profile, targeting metabolically active tumors and hypoxic tumor regions. It has been evaluated in more than 450 patients in multiple clinical studies. Data from a previous phase III trial indicated a 25% improvement in median survival in a very difficult to treat indication, 2nd line pancreatic cancer, although the study size and trial design was insufficient to prove statistical significance.
A key finding of the prior phase III study was the shortened survival associated with glufosfamide treatment of insulin-taking patients (43 of 303 test subjects). Glufosfamide is a glucose-conjugated prodrug, its activity affected by a patient’s diabetic status and use of insulin. Based on this and other valuable information from the prior study, and with assistance from key clinical oncologist advisors, Eleison has designed a new clinical study and regulatory plan for glufosfamide with a high probability of achieving statistical significance and regulatory approval. Eleison received an Agreement Letter from the FDA in response to the company’s Special Protocol Assessment (SPA) request, and plans to begin enrolling patients in its phase III 2nd line study in mid-2013
what does this have to do with current Glufosfamide trial that is probably going to have data next year?
all im saying is that we licensed it to Elesion and that it will cost us NOTHING and earn up to 50 percent profits If and that is a BIG IF this current trial somehow works.
and there is nothing wrong with being short.. they are kicking your arse at the moment.
i just don't get you lol. really. you need to take some chill pill.